Ascendis Pharma delivered strong top-line growth in Q3 2025 with total revenue of €213.6 million, largely driven by commercial success of YORVIPATH and SKYTROFA. However, despite an operating profit of €11 million, the company posted a net loss due to substantial finance expenses.

Ascendis Pharma delivered strong financial results in Q2 2025, with total revenue reaching €158.0 million, a substantial increase from the previous year, primarily due to the robust performance of YORVIPATH and SKYTROFA. The company also made significant strides in its clinical development, with TransCon CNP under FDA Priority Review and planned label expansions for SKYTROFA.

Ascendis Pharma reported a net loss of €94.6 million for the first quarter of 2025, an improvement from the €131.0 million net loss in the same period of 2024. Total revenue increased to €101.0 million, driven by strong product revenue from SKYTROFA and the commercial launch of YORVIPATH. The company ended the quarter with €518 million in cash and cash equivalents.